Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Natera Inc - SIC # 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
NTRA
Nasdaq
2835
https://www.natera.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Natera Inc
Natera (NTRA) Rose on Momentum in the Oncology Market
- Apr 24th, 2024 12:36 pm
Insider Sell: CFO Michael Brophy Sells Shares of Natera Inc (NTRA)
- Apr 24th, 2024 6:38 am
CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA)
- Apr 24th, 2024 6:38 am
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
- Apr 22nd, 2024 12:00 pm
Insider Sell: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA)
- Apr 18th, 2024 6:05 am
TipRanks’ ‘Perfect 10’ List: Analysts See Opportunity in These 2 Top-Scoring Stocks
- Apr 17th, 2024 12:31 pm
Estimating The Fair Value Of Natera, Inc. (NASDAQ:NTRA)
- Apr 12th, 2024 11:51 am
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
- Apr 11th, 2024 12:00 pm
11 Best Biotech ETFs To Buy
- Apr 9th, 2024 11:37 am
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
- Apr 8th, 2024 12:00 pm
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
- Apr 5th, 2024 11:00 am
Is Natera (NTRA) On The Cusp Of Being Cash Flow Positive?
- Apr 5th, 2024 9:15 am
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
- Apr 1st, 2024 12:00 pm
11 Best Healthcare ETFs To Buy Now
- Mar 21st, 2024 2:25 pm
Will Natera (NTRA) Continue to Deliver Solid Topline Growth?
- Mar 20th, 2024 9:46 am
Genetic Testing Stock Nears Buy Point After Earnings Gap-Up And 45% Gain
- Mar 18th, 2024 7:39 pm
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
- Mar 18th, 2024 11:00 am
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
- Mar 14th, 2024 12:00 pm
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
- Mar 12th, 2024 12:00 pm
SEC and Chief Legal Officer Daniel Rabinowitz Sells Shares of Natera Inc (NTRA)
- Mar 8th, 2024 6:31 am
Scroll